Recent Updates
Recently added Catalysts

Sjögren's Disease: 4 biotech companies with clinical-stage programmes

Immunology & InflammationConcentrated betData as of 2026-09-04

Competitors4in the clinic
Median market cap$1.7Buniverse median $1.20B
Allocated capital$4.4B$12.9B competing
Phase 3 or filed11 mid, 2 early
Pure plays1this indication only
Capital rank43/299crowding rank 47

Sjögren's Disease is a concentrated bet: only 4 US-listed developers are in the clinic, and the median one is worth $1.7B against a $1.20B universe median.

Scarcity is doing the work in that number. A thin field means an approval is shared with fewer rivals, and the market pays a premium for that position.

IMVT carries 63% of the $12.9B competing here, more than the other 3 companies combined.

$4.4B of allocated capital sits in Sjögren's Disease, 43rd of 299 indications, and 1 of the 4 companies are pure plays that trade on this indication alone.

Companies developing drugs for Sjögren's Disease 4

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
VORVor BiopharmaTelitaciceptPhase 31$1.4BNo2 30 Jun 2027
IMVTImmunovantIMVT-1402Phase 21$8.1BNo5 31 Dec 2026
LKFTLakefront BiotherapeuticsOM336Phase 11$1.9BYes1No dated event
CGEMCullinan TherapeuticsCLN-978Phase 11$1.4BNo8 14 Sep 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile. IMVT holds 63% of the $12.9B competing in this indication.

Why Sjögren's Disease is a concentrated bet

Few competitors, each one large. The market pays a scarcity premium to compete here.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Sjögren's Disease has 4 competitors and a median of $1.7B.

Immunology & Inflammation

Immunology & Inflammation holds $139B of the map's capital, 20.7% of the total, spread across 51 indications and 82 companies. 23 of those indications have more than one company competing.

See every Immunology & Inflammation indication on the map

Related indications in Immunology & Inflammation

Crohn's Disease4 companies · $5.1B · median $714MOrphan cornerThyroid Eye Disease2 companies · $3.6B · median $2.8BConcentrated betIgA Nephropathy4 companies · $3.6B · median $1.8BConcentrated betAndrogenetic Alopecia2 companies · $5.6B · median $2.8BConcentrated betIdiopathic Pulmonary Fibrosis7 companies · $5.8B · median $1.3BGold rushWarm Autoimmune Hemolytic Anemia2 companies · $2.4B · median $3.8BConcentrated betAlopecia Areata3 companies · $2.2B · median $1.6BConcentrated betWrinkles1 company · $2.2B · median $11.0BUncontested

Sjögren's Disease pipeline questions

Which biotech companies are developing drugs for Sjögren's Disease?

Vor Biopharma (VOR, Telitacicept, Phase 3); Immunovant (IMVT, IMVT-1402, Phase 2); Lakefront Biotherapeutics (LKFT, OM336, Phase 1); Cullinan Therapeutics (CGEM, CLN-978, Phase 1). Those are the 4 US-listed developers in the $100M to $20B market cap band with a clinical-stage programme in Sjögren's Disease.

How advanced is the Sjögren's Disease pipeline?

Of the 4 clinical-stage programmes in Sjögren's Disease, 1 is in Phase 3 or filed, 1 is in mid-stage development and 2 are in early-stage development.

Which company leads the Sjögren's Disease field?

IMVT is the largest developer in Sjögren's Disease, holding 63% of the $12.9B of market capitalisation competing in the indication. The median competitor is worth $1.7B.

When is the next Sjögren's Disease catalyst?

The next dated catalyst in Sjögren's Disease is CGEM on 14 Sep 2026. 3 dated events across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map